Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Shares of Bristol-Myers Squibb BMY, +0.37% gained 4.2% in premarket trading on Thursday on better-than-expected earnings and a positive patent ruling for its blockbuster blood thinner Eliquis that was announced Wednesday evening.

Bristol-Myers Squibb's stock is up on better-than-expected earnings

Bristol Myers Squibb Co raised its annual profit forecast on Thursday on hopes of a recovery in demand for its hospital-administered drugs, which had dropped as patients stayed away from doctors' offices due to the COVID-19 pandemic.

Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Second Quarter 2020 Financial Results

Bristol Myers Squibb Reports Second Quarter 2020 Financial Results

Pfizer

Bristol-Myers Squibb Co. BMY, +0.37% shares rallied in the extended session Wednesday after a federal judge ruled for it and Pfizer Inc.

Bristol-Myers, Pfizer stocks rise on blood-thinner patent win

Apple

A Dangerous Dividend Blue-Chip You Should Ignore And A Great Alternative That's Set To Soar

Asbury Automotive Group

Meritage Homes

PennyMac Financial Services

While comparing stocks, if other factors are similar, the stock with a higher earnings yield is considered undervalued.

Grab These 4 High Earnings Yield Stocks for Solid Returns

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Bristol-Myers (BMY) This Earnings Season?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

Thanks to its Celgene acquisition, Bristol-Myers Squibb looks attractive ahead of earnings. Here's why you should buy BMY stock.

Bristol-Myers Squibb Is a Dirt-Cheap Buy Before Earnings

Ahead earnings, Bristol-Myers Squibb is a great value play. In fact, BMY stock is worth 30%-70% more than its current share price.

Bristol-Myers Squibb Has Great Potential Ahead of Earnings

Bristol Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Growth Investors Shouldn't Overlook Bristol Myers (BMY)

Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?

BMY vs. HZNP: Which Stock Is the Better Value Option?

BMY vs. HZNP: Which Stock Should Value Investors Buy Now?

Bausch Health Companies Inc

Cooper Companies

Medtronic

Envista Holdings Corp

These 5 healthcare stocks look like the sector's best, with downside protection and room for price appreciation even if the market falters.

5 Healthcare Stocks for Good (Portfolio) Health

CVS Health

Disney

Uber

Activision Blizzard

Beyond Meat

Clorox

Roku

Block

Here, 24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week.

Bristol-Myers, CVS, Disney, Uber and More Major Earnings Coming This Week

Best Buy

PulteGroup

Taiwan Semiconductor Manufacturing

Werner Enterprises

The dividend growth stocks have superior fundamentals that make dividend growth a quality and promising investment for the long term.

5 Solid Dividend Stocks That Promise Growth

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Board Elects Two New Independent Directors

Bristol Myers Squibb Board Elects Two New Independent Directors

bluebird bio

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma

Abbott Labs

Illumina

These companies have proven they can rebound from the worst.

3 Rock-Solid Healthcare Stocks to Buy in a Market Crash

Centene

Edwards Lifesciences

Novartis

UnitedHealth Group

Last week, the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the second quarter of the year.

The Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund

AstraZeneca

Eli Lilly

Each of these big drugmakers offers strong growth prospects and solid dividends.

3 Top Pharma Stocks to Buy Right Now

BMY stock looks cheap here. Bristol-Myers is a defensive value with an attractive yield, cheap valuation, and plenty of potential upside.

Undervalued Bristol-Myers Squibb Stock Is Worth 50% More

Western Digital

You don't need a fortune to make one with these exceptional companies.

3 Great Stocks to Invest In With $500 Right Now

Cigna

Sunoco

Vale S.A.

The earnings potential of a stock is an important consideration while making investment decisions. This makes the Earnings Yield ratio a handy tool for stock selection.

Level Up Your Portfolio With These High Earnings Yield Picks

Bristol-Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Bristol-Myers Squibb Shows Improved Relative Strength; Still Shy Of Benchmark appeared first on Investor's Business Daily.

News for Bristol-Myers Stock (BMY)